California State Teachers Retirement System 13F: Cuts ABT Stake by $6.2M

The California State Teachers Retirement System has trimmed its position in Abbott Laboratories (NYSE: ABT) by 67,702 shares, now holding 2,675,057 shares valued at approximately $243.2 million. This change represents a decrease of about 2.5% in its total investment. The latest filing reflects the fund's holdings as of May 18, 2026, and may not represent its current position.

What Changed in California State Teachers Retirement System's Abbott Laboratories Position

The California State Teachers Retirement System reduced its stake in Abbott Laboratories by 67,702 shares, down from 2,742,759 shares. This reduction points to a minor adjustment in its investment strategy but still keeps a substantial amount of shares in the company. The fund's average cost basis for this holding is $38.75.

Other Institutional Activity in Abbott Laboratories

Several other major institutional investors have also made moves regarding Abbott Laboratories. Blackrock Inc. grew its holdings by 6,876,428 shares, ending with 152,563,476 shares worth about $15.9 billion. Vanguard Capital Management LLC added 801,938 shares, bringing its total to 113,750,994 shares valued at approximately $11.9 billion. State Street Corporation increased its stake by 1,352,749 shares, totaling 80,926,234 shares valued at about $8.5 billion. Charles Schwab Investment Management, Inc. made a significant increase of 14,173,548 shares, bringing its total to 59,674,507 shares worth around $6.2 billion. Vanguard Portfolio Management LLC also added 1,073,944 shares, totaling 49,017,866 shares valued at approximately $5.1 billion.

Abbott Laboratories Stock Down 11.2%

Abbott shares are currently trading around $90.90, which is notably lower than its 52-week high of $132.03, indicating a decline in value over the past year. The stock has been performing below its 50-day moving average of about $105.93, suggesting that it may be experiencing some volatility. Investors may be watching for a potential rebound as the stock remains well above its 52-week low of $81.97.

Recent Earnings

Abbott Laboratories reported revenue of approximately $46.6 billion, with a revenue growth rate of 13%. The company's earnings per share (EPS) was reported at $3.10, while its net margin stood at 11.6%. The next earnings report is set for October 21, 2026, providing a timely update on the company's financial performance.

Insider Buying and Selling at Abbott Laboratories

Recent insider activity shows that executives at Abbott have been active in the market. CEO Robert B. Ford sold 398,832 shares on August 25, 2026, valued at approximately $46.2 million. Additionally, Officer John A. Mccoy Jr. sold 27 shares on September 2, 2026, for $2,958. On August 11, 2026, Officer Louis H. Morrone sold 5,850 shares at an average price of $109.83, totaling about $642,506. Notably, Director John G. Stratton bought 2,000 shares on May 7, 2026, at $86.82, valued at $173,640.

Analysts Set New Price Targets

Analysts have been optimistic about Abbott Laboratories in recent weeks. On October 16, 2026, TD Cowen reiterated its Buy rating for the stock with a price target of $135. On October 7, 2026, Barclays initiated coverage with an Overweight rating and a target of $120. Rothschild & Co upgraded its rating to Buy with a target of $127 on October 2, 2026. The consensus among analysts remains strong, with a recommendation of "strong buy" and a mean price target of $120.71.

About Abbott Laboratories

Abbott Laboratories, based in Abbott Park, Illinois, is a global healthcare company that focuses on discovering, developing, manufacturing, and selling a diverse range of healthcare products. Its primary areas of operation include pharmaceuticals, diagnostics, nutrition, and medical devices. With a market cap of about $181.1 billion, Abbott continues to play a significant role in the healthcare sector.

Bottom Line

Looking ahead, investors will want to keep an eye on Abbott Laboratories' next earnings report set for October 21, 2026. This 13F filing reflects past holdings, and future changes may not be captured until the next report. Analysts generally remain positive about the company's outlook, which may influence future buying or selling decisions.